ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow -3.3% ·
net new positions -7.7%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 100 | +1 | 15.23M | $1.21B | +7 | −7 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | n/a |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | n/a | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | n/a |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | n/a | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | n/a | −3 |
| Q2 2024 | 12 | n/a | 1.26M | $80.52M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.58M | n/a | $168.38M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 2 | The Vanguard Group ✦ (passive) | 1.28M | n/a | $83.35M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Millennium Management ✦ | 1.00M | +22.7% | $65.50M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 716.12K | +0.2% | $46.73M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 569.63K | -21.2% | $37.17M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Geode Capital Management ✦ (passive) | 427.55K | -0.5% | $27.90M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 128.39K | -41.5% | $8.38M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 68.29K | -70.3% | $4.46M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 18.60K | +32.2% | $1.21M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 10 | Norges Bank ✦ (passive) | 9.59K | 0.0% | $625,421 | 0.0% | Held | 2 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 9.22K | +14.0% | $602,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | Wellington Management ✦ | 7.88K | -4.0% | $514,237 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 13 | Fidelity (FMR) ✦ | 3.63K | n/a | $237,201 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $942,589 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4 holders, 27.49M shares, $50.55M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 5.40K sh · $388,206
Officer · 500 sh · $36,795
Officer · 2.85K sh · $208,050
Officer, Director · 5.40K sh · $383,400
Officer · 500 sh · $35,395
Director · 1.00K sh · $71,530
Officer · 2.85K sh · $207,480
Officer, Director · 5.40K sh · $401,220
Officer · 500 sh · $37,740
Officer · 3.16K sh · $243,474
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology